ReviewThe FEBS journal2025
Realizing the promise of 'La Dolce Vita' via chemical biology: glycan-motif editing of sLe
Review in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Structure, function, and implications of fucosyltransferases in health and disease.Nature communications · 2025Review
- Chemical Strategies to Custom-Modify α(1→3)-Fucosylated Glycan Motifs of the Human Glycocalyx.JACS Au · 2025Review
- Aberrant sialic acid metabolism promotes metabolic reprogramming and metastasis in breast cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The convergence of glycochemistry and glycobiology is enabling the creation of new therapeutic approaches with unprecedented capacity to alter cell and organismic biology using strategies that can uniquely and specifically custom-modify the expression of key cell surface glycan motifs. We define this evolving field of chemical biology as 'glycan-motif editing', and one of the principal targets of this glycoengineering effort is the sialofucosylated terminal lactosaminyl glycan known as sLe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.